**Supplementary Figure S1** EGFR IHC percent positive cells.
Histogram of IHC staining of percent positive cells in patients with EGFR IHC
results.

Supplementary Figure S2 Sensitivity analysis of OS censoring at the start of post-study docetaxel**.**
OS censoring at the start of post-study docetaxel (EGFR>0 subpopulation).
Abbreviations: HR=hazard ratio; CI=confidence interval.

HR (95% CI): 0.75 (0.62, 0.89); *P*=0.001

Median OS, months:
Necitumumab plus gemcitabine-cisplatin: 12.9
Gemcitabine-cisplatin: 10.9

necitumumab plus gemcitabine-cisplatin
gemcitabine-cisplatin

Supplementary Figure S3 Subpopulation treatment effect pattern plot analyses of hazard ratios for OS and PFS.
OS (A) and PFS (B) based on EGFR IHC percent positive. Note: Analyses are stratified.